IGeneX – The Most Comprehensive Testing Criteria for Detecting Lyme Disease

Testing at IGeneX covers a wider spectrum of Lyme Borrelia species.  We look for more and detect more with our in-house developed tests.

Most labs use the CDC recommended tests for Western Blots.

At IGeneX, we have developed unique Western Blot tests using two strains of B. burgdorferi.  This allows us to detect most B. burgdorferi infection (Lyme) in the United States, Canada, Europe, and Australia. 


IGeneX and the CDC recommended Lyme serology tests detect IgG and IgM antibodies in patient’s serum or plasma.

  • IgM antibody is the first antibody to appear in response to initial exposure or re-exposure to B. burgdorferi
  • IgG antibody develops as a late response to the infection.

Western Blot IgG or IgM test is an immunoblot that detects specific antibodies from patient’s serum or plasma.  Lyme bacterial antigens are present on the Western blot strip.  Lyme specific antibodies, if present in patient’s serum or plasma, bind to Lyme bacterial antigen present on the WB strip.  The bound antibody to specific protein bands on the Western blot strip is detected with specific reagents.  Combination of specific protein (band-kDa) present on the WB strip will identify if a patient has been exposed to B. burgdorferi.  The CDC criteria for detecting specific protein (band-kDa) combination is very stringent.  IGeneX Western blots are designed to detect antibodies to more relevant and broader range of antigens covering the full spectrum of the disease (early to late/chronic disease).  This is based on years of clinical experience and extensive validation of well characterized samples. 


IGeneX result criteria produce a higher sensitivity for detecting Lyme exposure.

With IGeneX, this combined result criteria of more significant specific proteins and 2 strains of B. burgdorferi comprises the most comprehensive testing for Lyme disease.